CAR T-Cell Therapy Decisions in B-ALL: The Role of Obe-Cel in B-ALL Treatment

EP: 1.CAR T-cell Therapy for B-ALL

EP: 2.Navigating Treatment Selections for B-ALL: Insights From the Moffitt Cancer Center

EP: 3.The Multidisciplinary Approach to CAR T-Cell Therapy for B-ALL

EP: 4.CAR T-Cell Therapy for B-ALL: Roles Within the Multidisciplinary Care Team

EP: 5.Optimizing Molecular Profiling for B-ALL Treatment

EP: 6.Multidisciplinary Clinical Perspectives: Factors That Influence CAR T-Cell Sequencing in B-ALL

EP: 7.Considerations Regarding Bridging Therapy for B-ALL CAR T-Cell Treatment

EP: 8.Obe-Cel for B-ALL: Insights Regarding Persistence, Toxicity, and Remission

Now Viewing

EP: 9.CAR T-Cell Therapy Decisions in B-ALL: The Role of Obe-Cel in B-ALL Treatment

EP: 10.Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL

EP: 11.Treatment Sequencing Decisions for B-ALL: Perspectives From Moffitt Cancer Center

EP: 12.Future Considerations for Treatment Sequencing in B-ALL

Video content above is prompted by the following:

When weighing the clinical advantages and adverse event risks of various CAR T-cell therapies, to what degree do the respective safety profiles influence final selection?

• What other patient and/or disease factors may affect that decision?
• How does the multidisciplinary team communicate with its members on procedural issues, clinical decisions, responsible parties, and next steps in the CAR T-cell therapy process?

Following patient reevaluation and lymphodepletion, do you routinely adopt tumor burden–guided dosing of CAR T-cell therapy?